Organization (Industry)
UNITED THERAPEUTICS Corp
ClinicalTrials.gov lists UNITED THERAPEUTICS Corp as lead sponsor of 91 trials, counting the companies grouped under it. UNITED THERAPEUTICS Corp itself has 33 active development programs and 18 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers UNITED THERAPEUTICS Corp and 2 companies grouped under it: 91 lead-sponsored trials (83 its own, 8 in the grouped companies) and 4 legal-entity registrations (3 its own, 1 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Miromatrix Medical (United States) | 6 | 1 |
| Lung Bioengineering Inc. | 2 | 0 |
Disease areas (41)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hypertension, Pulmonary | 78 |
| Pulmonary Arterial Hypertension | 57 |
| Hypertension | 42 |
| Lung Diseases, Interstitial | 13 |
| Neuroblastoma | 9 |
Showing 5 of 41 disease areas.
Trials by start year as sponsor or collaborator (25)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 3 |
| 2019 | 8 |
| 2018 | 5 |
| 2017 | 10 |
Showing 10 of 25 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (33)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Inhaled Treprostinil | Lung Diseases, Interstitial | Phase 3 | 6 |
| Ralinepag | Pulmonary Arterial Hypertension | Phase 3 | 5 |
| Ralinepag | Hypertension, Pulmonary | Phase 3 | 5 |
| Inhaled Treprostinil | Idiopathic Pulmonary Fibrosis | Phase 3 | 3 |
| Inhaled Treprostinil | Pulmonary Fibrosis | Phase 3 | 3 |
Showing 5 of 33 active programs.
Approved assets (18)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Treprostinil | 11 |
| Inhaled Treprostinil | 11 |
| Oral Treprostinil | 10 |
| Parenteral Treprostinil | 1 |
| Subcutaneous Treprostinil | 1 |
Showing 5 of 18 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=25) | 30% on time (n=23) |
Journals published in (55)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Pulmonary circulation | 10 |
| American journal of respiratory and critical care medicine | 7 |
| Arthritis and rheumatism | 7 |
| Chest | 6 |
| The New England journal of medicine | 6 |
Showing 5 of 55 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 129 | 35 | 2025-12-09 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 3,182,700,000 | 1,334,700,000 | 550,000,000 |
| 2024 | 2,877,400,000 | 1,195,100,000 | 481,000,000 |
| 2023 | 2,327,500,000 | 984,800,000 | 408,000,000 |
| 2022 | 1,936,300,000 | 727,300,000 | 322,900,000 |
| 2021 | 1,685,500,000 | 475,800,000 | 540,100,000 |
| 2020 | 1,483,300,000 | not reported | 357,700,000 |
| 2019 | 1,448,800,000 | not reported | 1,182,600,000 |
| 2018 | 1,627,800,000 | not reported | 357,900,000 |
| 2017 | 1,725,300,000 | not reported | 264,600,000 |
| 2016 | 1,598,800,000 | not reported | 147,600,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (14)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-09 | Other financing | not disclosed | Sec extracted |
| 2025-08-01 | Other financing | not disclosed | Sec extracted |
| 2025-04-25 | Debt financing | 200,000,000 | Sec extracted |
| 2024-03-29 | Debt financing | not disclosed | Sec extracted |
| 2024-03-29 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 14 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 16 |
FDA recalls (3)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Tyvaso Inhalation System Patient a) Starter Kit with TYVASO (treprostinil) Inhalation Solution. Treprostinil 1.74 mg/2.9 mL (0.6 mg/mL) (NDC 66302-206-01) b) TD-300/A Replacement Device Kit Material Number RTP3099 RX Only. Manufactured by United Therapeutics Corporation Research Triangle Park, NC 27709 | Class III | 2018-08-14 |
| TYVASO (treprostinil) Inhalation Solution Treprostinil 1.74 mg/2.9 mL (0.6 mg/mL) Tyvaso Inhalation System Starter Kit Model# TD-100/A, Rx Only, Manufactured by United Therapeutics Corporation Research Triangle Park, NC 27709, NDC# 6630220601 | Class II | 2017-09-11 |
| Tyvaso (treprostinil) Inhalation Solution, Treprostinil 1.74 mg/2.9 mL, Four 2.9 mL Ampules, For Oral Inhalation Use Only, Manufactured for United Therapeutics Corporation, Triangle Park, NC 27709 | Class II | 2014-03-28 |
Manufacturing and distribution sites (5)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| United Therapeutics Corporation | Durham, US | FDA | |
| United Therapeutics Corporation | Beltsville, US | FDA, Health Canada | |
| United Therapeutics Corporation | Silver Spring, US | FDA, Health Canada | |
| United Therapeutics Corporation | Research Triangle Park, US | Health Canada | |
| United Therapeutics Corporation | Morrisville, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (31)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| New Approaches to Neuroblastoma Therapy Consortium | Co sponsors trial with | 4 |
| Government of the United States of America | Co sponsors trial with | 4 |
| Nationwide Children's Hospital | Co sponsors trial with | 2 |
| Stanford University | Co sponsors trial with | 2 |
| Mayo Clinic | Co sponsors trial with | 2 |
Showing 5 of 31 relationships.
Latest dated events (284)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-09 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-04 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 284 events.
Biomarker capability evidence (225)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| AGT | Trial sponsor | Named in trial inclusion criteria |
| APC | Trial collaborator | Named in trial inclusion criteria |
| APC | Trial collaborator | Named in trial inclusion criteria |
| APOH | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 225 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.